Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring substance that has garnered significant attention in clinical research studies specifically those interested in producing a sleep peptide. Its potential to enhance sleep-related parameters has been well-documented, making it a potential avenue for addressing insomnia. Studies have consistently demonstrated that DSIP can effectively increase both total sleep time and sleep efficiency in individuals struggling with insomnia. Furthermore, its unique properties have shown promise in reducing sleep latency and minimizing episodes of awakening after sleep onset.
Beyond its impact on insomnia, DSIP has demonstrated noteworthy benefits for individuals with narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness. Notably, DSIP has exhibited the ability to enhance daytime performance in people with narcolepsy, alleviating their debilitating symptoms. This intriguing outcome has led researchers to hypothesize that DSIP may play a vital role in regulating sleep and wake cycles, suggesting its potential to modulate the delicate balance between these two states.
Still, DSIP is not recommended for human consumption since more in-depth studies are needed to determine its efficacy. Buy DSIP for research purposes only.
DSIP Product Details
The neuropeptide delta sleep-inducing peptide (DSIP) was discovered in the rabbit brain in 1963 and isolated from cerebral venous blood in 1977. Extensive research has revealed that DSIP is primarily synthesized in the hypothalamus, highlighting its physiological relevance.
In terms of its presence in the bloodstream, DSIP is found in relatively small quantities. Its levels fluctuate throughout the day, with higher concentrations typically observed in the afternoon. Interestingly, DSIP has also been identified in human milk, where its concentrations range from 10 ng m/L to 30 ng m/L, indicating its potential role in early development.
One intriguing characteristic of DSIP is its ability to cross the blood-brain barrier, as demonstrated in preclinical studies. Additionally, DSIP has shown remarkable stability during gut absorption, with no denaturation by enzymes. Importantly, DSIP has been found to induce only mild side effects, making it a well-tolerated peptide, and no withdrawal symptoms have been reported.
Clinical investigations have provided further evidence of DSIP’s therapeutic potential. In a study involving individuals with insomnia, the administration of DSIP was shown to increase sleep duration while reducing sleep disturbances and latency. Similarly, in a separate study involving healthy adults, DSIP was found to decrease sleep onset time and enhance sleep duration and efficiency.
These findings collectively underscore the significant impact of DSIP on sleep-related parameters and emphasize its potential as a valuable tool in the management of sleep disorders. Further research and exploration of DSIP’s mechanisms and therapeutic applications hold promise for improving sleep quality and addressing related issues.
- CAS Number 62568-57-4
- Molar Mass 848.8 g/mol
- Chemical Formula C35H48N10O15IUPAC NameDL-tryptophyl-DL-alanyl-glycyl-glycyl-DL-alpha-aspartyl-DL-alanyl-DL-seryl-glycyl-DL-glutamic acid
Key Features of DSIP
- 98% Purity
Potential Benefits of DSIP
Delta sleep-inducing peptide and Schizophrenia
In a clinical investigation comparing cerebrospinal fluid (CSF) levels of DSIP in healthy test subjects demonstrating symptoms of schizophrenia. It was found that those with schizophrenia had significantly lower CSF levels of DSIP than the healthy group. This suggests a potential link between DSIP and the central nervous system functioning in individuals with schizophrenia. [R][R]
In another study, DSIP is said to decrease spontaneous tumor incidence among mice with mammary carcinomas and leukemias. [R]
Delta sleep-inducing peptide and Normal Sleep Patterns
Phase-1 studies conducted on healthy test subjects revealed that DSIP enhanced sleep and maintained its effects on sleep functions for up to 20 hours post-injection. These studies demonstrated that DSIP was well-tolerated with no reported side effects. Preclinical investigations further showed that DSIP increased deep slow wave sleep (S2) while reducing light slow wave sleep (S1), without significant effects on REM and NREM sleep cycles. [R][R][R]
Delta sleep-inducing peptide and Pain Perception
Clinical research on DSIP therapy for chronic pain syndromes showed positive outcomes in 6 out of 7 test subjects with various types of discomfort, including migraine headaches, vasomotor headaches, foot pain, and tinnitus. Patients reported reduced pain perception and improved mood, with these changes persisting for up to 91 days. [R][R]
Delta sleep-inducing peptide and Major Depressive Disorder
Similar to the findings in schizophrenia, test subjects with major depressive disorder (MDD) also exhibited significantly lower CSF levels of DSIP compared to a healthy group. Additionally, DSIP levels in CSF showed an inverse correlation with sleep disturbance scores in depressed patients. Another study investigating plasma DSIP levels in suicidal patients with MDD reported elevated DSIP levels in MDD patients, with a significant correlation between DSIP and cortisol levels in healthy controls. [R][R][R]
Delta sleep-inducing peptide and Narcolepsy
Narcolepsy, characterized by excessive daytime drowsiness and sudden sleep attacks, can significantly impair an individual’s daily functioning. In a study involving a test subject exhibiting symptoms similar to a narcoleptic patient, repeated DSIP injections led to enhanced daytime activity, reduced frequency of sleep attacks, and improved daytime performance. [R]
DSIP and Somatostatin
One preclinical study investigated the interaction between DSIP and somatostatin, a protein that inhibits muscle growth. The study found that DSIP inhibited the release of somatostatin through a dopaminergic mechanism in muscle cells, potentially influencing muscle growth processes. [R]
Delta sleep-inducing peptide and Blood Pressure
A preclinical study explored the potential of DSIP to regulate blood pressure. The results indicated that DSIP treatment reduced heart rate and blood pressure levels in control rats, but had no significant effect on already depressed blood pressure levels in the other group. [R]
Delta sleep-inducing peptide and Insomnia
Several studies have explored the effects of DSIP on insomnia, yielding promising results. In a double-blind, placebo-controlled study, DSIP injections significantly increased sleep time by 22.5% and improved sleep efficiency by 26.8%. Additionally, DSIP administration reduced sleep latency by 53% and awakening after sleep onset by 45%. In another study, DSIP treatment improved sleep efficiency and shortened sleep latency compared to the placebo group. This effect could benefit chronic insomniac patients in the future. [R][R]
Moreover, a separate study reported that DSIP injections normalized sleep in 6 out of 7 test subjects with severe insomnia after a 14-day treatment period. [R]
How It Works
Delta sleep-inducing peptide (DSIP) exerts its effects through various mechanisms, each contributing to its diverse physiological impact on sleep patterns. First and foremost, DSIP has been found to increase delta-wave activity in the brain, which led to its naming as a sleep-inducing peptide. This effect, initially observed in rabbits and subsequently replicated in rats and mice, enhances the occurrence of slow, deep sleep characterized by delta waves. Such delta-wave activity is associated with the most restorative and healing stages of sleep, promoting overall sleep quality and rejuvenation.
In addition to enhancing delta sleep, DSIP has demonstrated the ability to increase rapid eye movement (REM) sleep. Notably, a preclinical study involving cats highlighted DSIP’s pronounced influence on REM sleep, which is characterized by rapid eye movements and is closely linked to processes such as dreaming and memory consolidation. By promoting REM sleep, DSIP potentially contributes to cognitive processes and emotional well-being during sleep.
Moreover, DSIP has shown efficacy in increasing non-REM (NREM) sleep, as observed in a pilot study involving humans. This neuropeptide exhibited the capacity to enhance both NREM and REM sleep, indicating its broad impact on sleep architecture. Notably, disturbances in NREM sleep have been associated with conditions such as Alzheimer’s and Parkinson’s disease, suggesting the potential therapeutic value of DSIP in such neurological disorders.
Another significant effect of DSIP is its ability to increase slow wave sleep (SWS), specifically stage three of NREM sleep. Preclinical investigations in cats have reported a substantial rise in SWS following DSIP administration. This stage of sleep, lasting between 70 and 90 minutes, represents a state of deep restfulness during which the body undergoes essential physiological recovery.
Overall, DSIP’s mechanism of action encompasses the promotion of delta-wave activity, increased REM sleep, enhancement of NREM sleep, and elevation of slow-wave sleep. By modulating these different sleep parameters, DSIP holds the potential to optimize sleep quality, cognitive functioning, and overall well-being. Further research is warranted to fully elucidate the intricate mechanisms underlying DSIP’s effects and its therapeutic implications for sleep disorders and neurodegenerative conditions.
When researching the use of DSIP Powder, it is essential to take certain precautions. Here are some precautions to keep in mind:
Observe best practices for studying research chemicals: Studying research chemicals requires a responsible and informed approach to ensure safety and meaningful scientific exploration. Research chemicals, also known as designer drugs or experimental compounds, are substances synthesized for scientific investigation or exploration of their properties.
Follow recommended dosage: Adhere to the recommended dosage instructions outlined on the product label. Avoid exceeding the suggested dose to minimize the risk of potential adverse effects among test subjects.
Safety and Side Effects
DSIP has generally been considered safe when administered appropriately. Preclinical studies have shown that it can cross the blood-brain barrier and be absorbed by the gut without significant denaturation by enzymes. It has also been reported to cause mild side effects and no withdrawal symptoms in studies conducted thus far.
The reported side effects of DSIP powder are minimal based on available research. However, it’s worth mentioning that individual responses may vary. Some potential side effects that have been mentioned in studies include slight drowsiness, sedation, and a feeling of relaxation. These effects are generally mild and transient.
In conclusion, DSIP (Delta sleep-inducing peptide) powder has shown promising benefits in improving various aspects of human sleep behavior. As a sleep-inducing peptide, DSIP has been studied for its effects on sleep onset mechanisms, sleep-wake cycles, and overall sleep quality. Notably, DSIP has demonstrated its potential to increase total sleep time, enhance sleep efficiency, and reduce sleep latency in individuals with chronic insomnia.
Furthermore, DSIP has exhibited acute and delayed effects on sleep promotion, with studies indicating its ability to normalize sleep patterns and reduce pronounced pain episodes. Its potential to normalize blood pressure levels and alleviate severe chronic insomnia has also been observed. As an unknown hypothalamic hormone, DSIP holds significant promise in improving sleep-related issues.
Importantly, DSIP has shown a favorable safety profile, with minimal reports of withdrawal symptoms or adverse reactions. Its actions primarily target the central nervous system, where it exerts direct inhibitory effects on sleep-related physiological processes. Additionally, DSIP has displayed stress-protective potency and immune system modulation, suggesting a broader scope of its primary function.
Although more research is needed to fully understand the mechanisms of DSIP and its effects on sleep and other physiological processes, clinical and laboratory studies have already provided valuable insights. DSIP’s ability to improve sleep patterns, inhibit somatostatin secretion, and promote restful sleep makes it a promising candidate for therapeutic applications in conditions such as major depression, pain management, and sleep disorders.
In summary, DSIP powder holds great potential as a sleep-promoting agent, with its effects on sleep behavior and related physiological functions being increasingly recognized. As research continues to unfold, DSIP may offer new avenues for addressing sleep disturbances and associated conditions, further advancing our understanding and treatment options for sleep-related disorders.
Please take note of the scientific applications of this product and carefully read our Terms and Conditions before making a purchase from RCD.bio. By completing your order and submitting payment, you agree to abide by the Terms and Conditions of our company. Please be aware that the product packaging may differ slightly from the images displayed on our website.
If for any reason you are not completely satisfied with the product you receive, please contact us at [email protected]. Our team is dedicated to ensuring satisfaction among our customers.
PLEASE NOTE: All products offered by RCD.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.